Please login to the form below

Not currently logged in
Email:
Password:

Lupin appoints European president

Maurice Chagnaud moves to India-based company from Teva

India-based Lupin has appointed former Teva senior VP Dr Maurice Chagnaud as president of its European business and head of inhalation strategy.

Dr Chagnaud will be based at the company's operations in Schaffhausen, Switzerland, where he will be responsible for Lupin's business strategy in Europe, including Russia and the CIS countries.

He will also be responsible for developing Lupin's core strategy for inhalation across all developed markets.

Prior to joining Lupin, Dr Chagnaud was senior VP, Central and Eastern Europe, at Israel-based Teva. He was with Teva for just under seven years, with other roles include chief commercial officer in Europe and CEO of the company's operations in France.

In addition, Dr Chagnaud's industry experience also includes time as general manager for Merck KGaA'a generics business in Italy.

20th February 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics